Aquaretic agents: What's beyond the treatment of hyponatremia?

Current Pharmaceutical Design

Volumn 13, Issue 8, 2007, Pages 865-871

  Bolignano, Davide ^a   Coppolino, Giuseppe ^a   Criseo, Manila ^a   Campo, Susanna ^a   Romeo, Adolfo ^a   Buemi, Michele ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Aquaretic; Heart failure; Hyponatremia; V2 antagonists; Vasopressin

Indexed keywords

5 FLUORO 2 METHYL N [5 (5H PYROLLOL[2,1 C][1,4]BENZODIAZEPINE 10(11H) YLCARBONYL) 2 PYRIDINYL]BENZAMIDE; AMIODARONE; AQUAPORIN 2; AQUARETIC AGENT; CL 385004; CONIVAPTAN; DIURETIC AGENT; ELECTROLYTE; KETOCONAZOLE; LIXIVAPTAN; MOZAVAPTAN; N [2 (1 MERCAPTOCYCLOHEXYL)ACETYL] DEXTRO O ETHYLTYROSYLPHENYLALANYLVALYLASPARAGINYLCYSTEINYLPROLYLARGININAMIDE DISULFIDE; N [4 [[(2 HYDROXY 2,3,3A,4 TETRAHYDROPYRROLOL[1,2 A]QUINOXALIN 5(1H) YL)CARBONYL]PHENYL] 4' METHYL 1(1,1' BIPHENYL) 2 CARBOXAMIDE]; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PLACEBO; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VP 343; WARFARIN;

ASCITES; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; HEART FAILURE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ANALYSIS; URINE VOLUME; WATER ABSORPTION;

ANIMALS; BENZAZEPINES; DIURESIS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; HYPONATREMIA; OSMOLAR CONCENTRATION; POLYCYSTIC KIDNEY DISEASES; RECEPTORS, VASOPRESSIN;

EID: 34247155435     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780363040     Document Type: Review

References (61)

1. Huang DY, Pfaff I, Serradeil-Le Gal C, Vallon V. Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 2000; 362(3): 201-7.
2. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999; 10(10): 2165-70.
3. Knepper MA, Nielsen S, Chou CL, DiGiovanni SR. Mechanism of vasopressin action in the renal collecting duct. Semin Nephrol 1994; 14: 302-21.
4. Sasaki S, Kuwahara M, Yamashita Y, Marumo F. Structure and function of AQP2. Nephrol Dial Transplant 2000; 15(Suppl 6): 21-2.
5. Buemi M, Corica F, Di Pasquale G, Aloisi C, Sofi M, Casuscelli T, et al. Water immersion increases urinary excretion of aquaporin-2 in healthy humans. Nephron 2000; 85: 20-6.
6. Buemi M, Di Pasquale G, Ruello A, Floccari F, Aloisi C, Latassa G, et al. Effect of a prostacyclin analogue, iloprost, on urinary aquaporin-2 excretion in humans. Nephron 2002; 91: 197-202.
7. Bouley R, Pastor-Soler N, Cohen O, McLaughlin M, Breton S, Brown D. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am J Physiol Renal Physiol 2005; 288(6): F1103-12.
8. Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors. Prog Brain Res 2002; 139: 179-96
9. Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002; 139: 197-210.
10. Kinter LB, Dytko G, Ashton D, McDonald J, Huffman W, Stassen F. Discovery and therapeutic utility of vasopressin antagonists in rats. J Cardiovasc Pharmacol 1986; 8(Suppl 7): S36-43.
11. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996; 98(12): 2729-38.
12. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287(3): 860-7.
13. Shimizu K. Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humans. Kidney Int 1995; 48(1): 220-6.
14. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003; 107(21): 2690-6.
15. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291(16): 1963-71.
16. Kondo K, Ogawa H, Yamashita H, Miyamoto H, Tanaka M, Nakaya K, et al. 7-Chloro-5-hydroxy-1-2-methyl-4-(2-methylbenzoyl-amino)benzoyl- 2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem 1999; 7: 1743-54.
17. Wang Z, Sekar K, Orlandi C, Bramer SL. Tolvaptan has no effect on steady state amiodarone concentrations. Clin Pharmacol Ther 2003; 73: P44.
18. Shoaf S, Kumara S, Mallikaarjun S, Orlandi C, Bramer S. Lack of effect of tolvaptan on pharmacokinetics (PK) and pharmacodynamics (PD) of warfarin. Clin Pharmacol Ther 2003; 73: P45.
19. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47(1): 1-8.
20. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, et al. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol 2005; 507(1-3): 145-51.
21. Takeuchi M, Lee JD, Shimizu H, Ueda T. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats. Int J Cardiol 2006; 108(2): 231-6.
22. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
23. Goldsmith SR. Vasopressin antagonists in CHF: ready for clinical trials? Cardiovasc Res 2002; 54: 13-5.
24. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47(8): 1615-21.
25. Kitiyakara C, Wilcox CS. Vasopressin V2-receptor antagonists: panaceas for hyponatremia? Curr Opin Nephrol Hypertens 1997; 6(5): 461-7.
26. Ishikawa S, Saito T, Kasono K. Pathological role of aquaporin-2 in impaired water excretion and hyponatremia. J Neuroendocrinol 2004; 16(4): 293-6.
27. Schrier RW, Fassett RG, Ohara M, Martin PY. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy. Proc Assoc Am Physicians 1998; 110(5): 407-11.
28. Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005; 146(7): 3037-43.
29. Fernandez-Varo G, Ros J, Cejudo-Martin P, Cano C, Arroyo V, Rivera F, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003; 38(6): 755-61.
30. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997; 82(4): 1054-7.
31. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, et al. Tolvaptan Investigators.Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97(7): 1064-7.
32. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66(3): 964-73.
33. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao S, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57(4): 1460-71.
34. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9(10): 1323-6.
35. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10(4): 363-4.
36. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16(4): 846-51.
37. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 1975; 292(8): 390-2.
38. Forrest JN Jr, Cox M, Hong C, Morrison G, Bia M, Singer I. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978; 298(4): 173-7.
39. Danovitch GM, Le Roith D, Glick S. Renal function during treatment of inappropriate secretion of antidiuretic hormone with demeclocycline. Isr J Med Sci 1978; 14(8): 852-7.
40. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980; 243(24): 2513-5.
41. Kazama I, Arata T, Michimata M, Hatano R, Suzuki M, Miyama N, et al. Lithium effectively complements vasopressin V2 receptor antagonist in the treatment of hyponatraemia of SIADH rats. Nephrol Dial Transplant 2007; 22(1): 68-76.
42. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290(2): F273-8
43. Burkhardt H, Bruckner D, Gladisch R. Risk factors of worsening renal function in hospitalized elderly patients. J Nephrol 2005; 18(2): 166-73.
44. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147(2): 331-8.
45. Chen HH, Redfield MM, Nordstrom LJ, Cataliotti A, Burnett JC Jr. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 2003; 284: F1115-9.
46. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 2003; 18: 169-74.
47. Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000; 292(1): 288-94.
48. Weinberger MH. Diuretics and their side effects. Dilemma in the treatment of hypertension. Hypertension 1988; 11(3 Pt 2): II16-20
49. Roald AB, Tenstad O, Aukland K. The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney. Acta Physiol Scand 2000; 168(2): 351-9.
50. Bellizzi V, Scalfi L, Terracciano V, De Nicola L, Minutolo R, Marra M, et al. Early changes in bioelectrical estimates of body composition in chronic kidney disease. J Am Soc Nephrol 2006; 17(5): 1481-7.
51. Sanders PW. Effect of salt intake on progression of chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15(1): 54-60.
52. Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, Arthus MF, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18(3): 497-506.
53. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18(9): 1755-63.
54. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: Outcome study with tolvaptan (EVEREST). J Card Fail 2005; 11(4): 260-9.
55. Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S, Bouby N. Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinology 2002; 143(7): 2759-66.
56. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin-receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006; 91(6): 2145-52.
57. Takeda T, Sawada S, Takeda S, Kitano H, Suzuki M, Kakigi A, et al. The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops. Heart Res 2003; 182(1-2): 9-18.
58. Lacheretz F, Barbier A, Serradeil-Le Gal C, Elena PP, Maffrand JP, Le Fur G. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension. J Ocul Pharmacol Ther 2000; 16(3): 203-16.
59. Griebel G, Stemmelin J, Gal CS, Soubrie P. Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharm Des 2005; 11(12): 1549-59.
60. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Des 2005; 11(2): 205-25.
61. Weber T, Auer J, Eber B. The diagnostic and prognostic value of brain natriuretic peptide and aminoterminal (nt)-pro brain natriuretic peptide. Curr Pharm Des 2005; 11(4): 511-25.